CERTIFICATE OF ANALYSIS

PuriLab Analytical

Retatrutide 40 mg

RT-2026-117 Lot ALRT01 Analyzed November 14, 2026

TIMELINE

ORDERED
November 10, 2026

RECEIVED
November 13, 2026

ANALYZED
November 14, 2026

SAMPLE

NAME
Retatrutide 40 mg

EXPECTED
Retatrutide

AMOUNT
1 vial, lyophilized powder

TESTING

CLIENT
Katerinne I

TEST TYPE
Content & purity

METHOD
HPLC-UV

CONTENT, HOW MUCH IS IN IT

45.86 mg

Label claim: 40 mg


PURITY, HOW CLEAN IT IS

>99.9%

Measured, not estimated. Purity is calculated from the full chromatogram shown above, and no impurity peaks were detected above the reporting threshold. Results of 99.95% or higher are reported as >99.9%, as 100% purity cannot be demonstrated analytically.

CHROMATOGRAM

HPLC-UV



- 17.91 min, Retatrutide, >99.9%

ANALYST COMMENTS

White lyophilized powder, yellow-cap vial labeled CRT3, received sealed.

ANALYST SIGNATURE

Max Barrett
Lab Director, PuriLab Analytical
Analysis date: November 14, 2026

VERIFICATION CODE

RT-SNN1-DHWQ

Verify at purilab.org/verify/RT-SNN1-DHWQ

SCAN TO VERIFY

RT-SNN1-DHWQ

Results apply solely to the sample as received and are not representative of any larger lot, batch, or production run. Findings are limited to the analytes stated above. PuriLab Analytical is an independent testing laboratory, is not CLIA certified or ISO 17025 accredited, does not sell or distribute any substance, and makes no representation as to the safety, legality, or fitness of any material for any use.